Tysabri® (natalizumab) data at ECTRIMS reaffirm positive effects of treatment for people with relapsing forms of MS Biogen Idec, 11 Oct 2012 Accessed on 16 Oct 2012 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1744038. CommentRecommendBookmarkWatch